Vicarious Surgical Inc (NYSE:RBOT) Receives Consensus Rating of “Buy” from Analysts

Vicarious Surgical Inc (NYSE:RBOTGet Rating) has received a consensus recommendation of “Buy” from the six research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $13.20.

A number of equities research analysts recently commented on RBOT shares. Zacks Investment Research lowered Vicarious Surgical from a “buy” rating to a “hold” rating in a research report on Saturday. Piper Sandler decreased their price target on Vicarious Surgical from $7.00 to $5.00 in a research report on Tuesday, May 10th.

In other Vicarious Surgical news, CTO Sammy Khalifa sold 6,830 shares of the company’s stock in a transaction on Thursday, April 14th. The stock was sold at an average price of $4.08, for a total transaction of $27,866.40. Following the transaction, the chief technology officer now owns 136,413 shares of the company’s stock, valued at approximately $556,565.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Adam David Sachs sold 8,537 shares of the company’s stock in a transaction on Monday, March 28th. The stock was sold at an average price of $4.23, for a total value of $36,111.51. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 35,842 shares of company stock worth $152,359.

Several hedge funds have recently bought and sold shares of RBOT. VK Services LLC acquired a new position in shares of Vicarious Surgical in the 3rd quarter valued at $293,386,000. Comprehensive Financial Management LLC bought a new stake in shares of Vicarious Surgical in the 3rd quarter valued at $33,472,000. Hel Ved Capital Management Ltd bought a new stake in shares of Vicarious Surgical in the 4th quarter valued at $12,962,000. Vident Investment Advisory LLC bought a new stake in shares of Vicarious Surgical in the 4th quarter valued at $11,399,000. Finally, BlackRock Inc. increased its position in shares of Vicarious Surgical by 38,688.7% in the 4th quarter. BlackRock Inc. now owns 817,277 shares of the company’s stock valued at $8,679,000 after buying an additional 815,170 shares in the last quarter. 35.25% of the stock is currently owned by institutional investors.

Shares of RBOT stock traded up $0.35 during trading hours on Thursday, hitting $4.02. The company had a trading volume of 15,533 shares, compared to its average volume of 371,233. Vicarious Surgical has a 12 month low of $3.05 and a 12 month high of $15.79. The firm’s fifty day moving average is $4.67 and its 200 day moving average is $7.57.

Vicarious Surgical (NYSE:RBOTGet Rating) last released its quarterly earnings data on Thursday, March 3rd. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.04). Sell-side analysts forecast that Vicarious Surgical will post -0.6 EPS for the current year.

Vicarious Surgical Company Profile (Get Rating)

Vicarious Surgical Inc operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Featured Stories

Receive News & Ratings for Vicarious Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicarious Surgical and related companies with MarketBeat.com's FREE daily email newsletter.